Phase 1, Phosphoinositide 3-kinase inhibitor, open-label crossover study
Showing 1 - 25 of >10,000
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +
Not yet recruiting
- Breast Cancer
- +3 more
- AI+CDK4/6i
- +7 more
-
Miami, FloridaUniversity of Miami
Apr 12, 2023
Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma Plexiform
-
Shanghai, China
- +1 more
Jan 13, 2023
Healthy Adults Trial in Daytona Beach (Adagrasib, Eltrombopag + adagrasib)
Recruiting
- Healthy Adults
- Adagrasib
- Eltrombopag + adagrasib
-
Daytona Beach, FloridaFortrea Clinical Research Unit Daytona Beach (Labcorp Clinical R
Jun 29, 2023
Relapsed or Refractory Lymphoma Trial in Austin (HMPL-523, Itraconazole, Rifampin)
Active, not recruiting
- Relapsed or Refractory Lymphoma
- HMPL-523
- +2 more
-
Austin, TexasPPD Austin
Jan 31, 2023
Healthy Adults Trial in Dallas (Treatment A, Treatment B)
Not yet recruiting
- Healthy Adults
- Treatment A
- Treatment B
-
Dallas, TexasLabcorp Clinical Research Unit Inc
May 11, 2023
Healthy Trial in Nottingham ([14C]-Paxalisib Capsule)
Active, not recruiting
- Healthy
- [14C]-Paxalisib Capsule
-
Nottingham, United KingdomQuotient Sciences
Aug 16, 2022
Metastatic Breast Cancer Trial in East Melbourne (BYl719)
Completed
- Metastatic Breast Cancer
-
East Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
Aug 11, 2022
Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation Trial in San Francisco (Alpelisib, Carboplatin,
Not yet recruiting
- Solid Tumors, Adult
- +7 more
- Alpelisib
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jul 21, 2022
Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))
Not yet recruiting
- Lung Cancer
- Non Small Cell Lung Cancer
- Amivantamab 1050mg
- +2 more
-
Aurora, Colorado
- +2 more
Apr 25, 2023
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +5 more
- PI3K inhibitor BYL719
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 14, 2022
Progressive Supranuclear Palsy, Corticobasal Syndrome Trial in San Francisco (Fasudil)
Active, not recruiting
- Progressive Supranuclear Palsy
- Corticobasal Syndrome
-
San Francisco, CaliforniaUniversity of California Weill Institute for Neurosciences
May 31, 2022
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available Trial
Completed
- Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
-
Houston, TexasM.D. Anderson Cancer Center
Aug 22, 2022
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer Trial (Q702, Pembrolizumab)
Not yet recruiting
- Esophageal Cancer
- +3 more
- Q702
- Pembrolizumab
- (no location specified)
Jun 27, 2022
Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)
Not yet recruiting
- Metastatic Breast Cancer
- +3 more
- OP-1250
- +2 more
- (no location specified)
Aug 18, 2022
Relapsed or Refractory Lymphoma Trial in Miami (Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg)
Completed
- Relapsed or Refractory Lymphoma
- Itraconazole 200 mg
- +3 more
-
Miami, FloridaQPS- Miami
Jan 12, 2023
Healthy Subject Trial in Fargo (SACT-1, EDURANT 25Mg Tablet)
Completed
- Healthy Subject
- SACT-1
- EDURANT 25Mg Tablet
-
Fargo, North DakotaNovum Pharmaceutical Research Services
May 22, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (HMPL-453, Rabeprazole)
Active, not recruiting
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaShanghai Xuhui Central Hospital
Jun 24, 2023
